159 related articles for article (PubMed ID: 37442992)
1. Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors.
Olateju OA; Zeng Z; Thornton JD; Mgbere O; Essien EJ
BMC Cancer; 2023 Jul; 23(1):655. PubMed ID: 37442992
[TBL] [Abstract][Full Text] [Related]
2. Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US.
Moyers JT; Patel A; Shih W; Nagaraj G
JAMA Netw Open; 2020 Sep; 3(9):e2015656. PubMed ID: 32876684
[TBL] [Abstract][Full Text] [Related]
3. Patterns of immunotherapy utilization for non-small cell lung cancer in Texas pre- and post-regulatory approval.
Olateju OA; Zeng Z; Zakeri M; Sansgiry SS
Clin Transl Oncol; 2024 Mar; ():. PubMed ID: 38554190
[TBL] [Abstract][Full Text] [Related]
4. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US.
Ermer T; Canavan ME; Maduka RC; Li AX; Salazar MC; Kaminski MF; Pichert MD; Zhan PL; Mase V; Kluger H; Boffa DJ
JAMA Netw Open; 2022 Jun; 5(6):e2219535. PubMed ID: 35771575
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy Treatment Disparities: A Texas Cancer Registry Analysis of Patients with Cutaneous Melanoma.
Ramirez F; Alvarado L; Dwivedi A; Chacon J
J Immigr Minor Health; 2024 Feb; 26(1):23-33. PubMed ID: 37615821
[TBL] [Abstract][Full Text] [Related]
6. Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors.
Jain V; Venigalla S; Reddy VK; Lukens JN; Mitchell TC; Shabason JE
J Immunother; 2020 Jan; 43(1):8-15. PubMed ID: 31498180
[TBL] [Abstract][Full Text] [Related]
7. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
Lamba N; Ott PA; Iorgulescu JB
JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
[TBL] [Abstract][Full Text] [Related]
8. Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma.
Krimphove MJ; Tully KH; Friedlander DF; Marchese M; Ravi P; Lipsitz SR; Kilbridge KL; Kibel AS; Kluth LA; Ott PA; Choueiri TK; Trinh QD
J Immunother Cancer; 2019 Nov; 7(1):289. PubMed ID: 31699149
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016.
Deng W; Wang Y; Liu X; Liu J; Wang L; Yang Z; Yang M; An Y; Tang C; Sanford NN; Kim BYS; Jiang W
JAMA Netw Open; 2020 Dec; 3(12):e2028627. PubMed ID: 33295975
[TBL] [Abstract][Full Text] [Related]
10. Changes in Utilization and Health Among Low-Income Adults After Medicaid Expansion or Expanded Private Insurance.
Sommers BD; Blendon RJ; Orav EJ; Epstein AM
JAMA Intern Med; 2016 Oct; 176(10):1501-1509. PubMed ID: 27532694
[TBL] [Abstract][Full Text] [Related]
11. Association of Receipt of Systemic Treatment for Melanoma With Insurance Type in North Carolina.
Adamson AS; Jackson BE; Baggett CD; Thomas NE; Haynes AB; Pignone MP
Med Care; 2023 Dec; 61(12):829-835. PubMed ID: 37708348
[TBL] [Abstract][Full Text] [Related]
12. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
13. Disparity in initiation of checkpoint inhibitors among commercially insured and Medicare Advantage patients with metastatic melanoma.
Li M; Liao K; Nowakowska M; Wehner M; Shih YT
J Manag Care Spec Pharm; 2023 Nov; 29(11):1232-1241. PubMed ID: 37889870
[No Abstract] [Full Text] [Related]
14. Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States.
Haque W; Verma V; Butler EB; Teh BS
J Immunother; 2019; 42(6):228-235. PubMed ID: 30985445
[TBL] [Abstract][Full Text] [Related]
15. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
16. Disparities and Impact of Medicaid Expansion on Left Ventricular Assist Device Implantation and Outcomes.
Wang X; Luke AA; Vader JM; Maddox TM; Joynt Maddox KE
Circ Cardiovasc Qual Outcomes; 2020 Jun; 13(6):e006284. PubMed ID: 32394720
[TBL] [Abstract][Full Text] [Related]
17. Disparities in Care Management During Terminal Hospitalization Among Adults With Metastatic Cancer From 2010 to 2017.
Deeb S; Chino FL; Diamond LC; Tao A; Aragones A; Shahrokni A; Yerramilli D; Gillespie EF; Tsai CJ
JAMA Netw Open; 2021 Sep; 4(9):e2125328. PubMed ID: 34550384
[TBL] [Abstract][Full Text] [Related]
18. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
[TBL] [Abstract][Full Text] [Related]
19. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
[TBL] [Abstract][Full Text] [Related]
20. Effects of treatment methods on cutaneous melanoma related mortality and all-cause mortality in Texas: TCR-Medicare 2007-2017 database.
Ramirez F; Riva H; Digbeu B; Samaniego M; Fernandez L; Mansour S; Vasquez R; Lopez DS; Chacon J
Cancer Causes Control; 2024 Feb; 35(2):265-275. PubMed ID: 37702966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]